vs
Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $57.2M, roughly 1.8× Vanda Pharmaceuticals Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs -246.8%, a 273.4% gap on every dollar of revenue. Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs 3.9%).
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
OBK vs VNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $57.2M |
| Net Profit | $27.7M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | — | -70.5% |
| Net Margin | 26.6% | -246.8% |
| Revenue YoY | — | 7.6% |
| Net Profit YoY | — | -2774.3% |
| EPS (diluted) | $0.89 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $103.4M | $57.2M | ||
| Q3 25 | $109.8M | $56.3M | ||
| Q2 25 | $83.5M | $52.6M | ||
| Q1 25 | $94.1M | $50.0M | ||
| Q4 24 | $78.3M | $53.2M | ||
| Q3 24 | $90.8M | $47.7M | ||
| Q2 24 | $96.4M | $50.5M |
| Q1 26 | $27.7M | — | ||
| Q4 25 | $29.5M | $-141.2M | ||
| Q3 25 | $8.6M | $-22.6M | ||
| Q2 25 | $14.6M | $-27.2M | ||
| Q1 25 | $22.4M | $-29.5M | ||
| Q4 24 | $14.3M | $-4.9M | ||
| Q3 24 | $18.6M | $-5.3M | ||
| Q2 24 | $21.0M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | 36.2% | -70.5% | ||
| Q3 25 | 10.0% | -55.6% | ||
| Q2 25 | 22.3% | -73.2% | ||
| Q1 25 | 30.4% | -82.0% | ||
| Q4 24 | 23.0% | -19.3% | ||
| Q3 24 | 26.1% | -23.1% | ||
| Q2 24 | 27.7% | -20.1% |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.5% | -246.8% | ||
| Q3 25 | 7.9% | -40.1% | ||
| Q2 25 | 17.5% | -51.7% | ||
| Q1 25 | 23.8% | -58.9% | ||
| Q4 24 | 18.2% | -9.2% | ||
| Q3 24 | 20.5% | -11.2% | ||
| Q2 24 | 21.8% | -9.0% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.95 | $-2.40 | ||
| Q3 25 | $0.27 | $-0.38 | ||
| Q2 25 | $0.47 | $-0.46 | ||
| Q1 25 | $0.71 | $-0.50 | ||
| Q4 24 | $0.45 | $-0.09 | ||
| Q3 24 | $0.60 | $-0.09 | ||
| Q2 24 | $0.67 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $327.2M |
| Total Assets | $10.2B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $424.2M | $84.9M | ||
| Q3 25 | $626.9M | $70.0M | ||
| Q2 25 | $334.1M | $81.0M | ||
| Q1 25 | $486.2M | $111.8M | ||
| Q4 24 | $470.2M | $102.3M | ||
| Q3 24 | $321.2M | $100.5M | ||
| Q2 24 | $288.1M | $103.0M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $327.2M | ||
| Q3 25 | $1.2B | $466.0M | ||
| Q2 25 | $1.2B | $486.3M | ||
| Q1 25 | $1.2B | $511.4M | ||
| Q4 24 | $1.1B | $538.5M | ||
| Q3 24 | $1.1B | $541.2M | ||
| Q2 24 | $1.1B | $542.5M |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $9.7B | $488.9M | ||
| Q3 25 | $9.8B | $601.1M | ||
| Q2 25 | $9.7B | $624.7M | ||
| Q1 25 | $9.8B | $631.9M | ||
| Q4 24 | $9.7B | $656.2M | ||
| Q3 24 | $10.0B | $645.1M | ||
| Q2 24 | $9.9B | $651.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $158.9M | $-29.4M | ||
| Q3 25 | $59.3M | $-31.6M | ||
| Q2 25 | $20.6M | $-15.3M | ||
| Q1 25 | $35.6M | $-33.1M | ||
| Q4 24 | $108.5M | $-1.8M | ||
| Q3 24 | $39.6M | $-14.6M | ||
| Q2 24 | $11.9M | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | $151.1M | $-29.5M | ||
| Q3 25 | $56.8M | $-31.8M | ||
| Q2 25 | $19.6M | $-15.6M | ||
| Q1 25 | $34.8M | $-33.6M | ||
| Q4 24 | $86.4M | $-2.0M | ||
| Q3 24 | $32.2M | $-14.7M | ||
| Q2 24 | $6.5M | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | 146.0% | -51.6% | ||
| Q3 25 | 51.7% | -56.5% | ||
| Q2 25 | 23.5% | -29.6% | ||
| Q1 25 | 37.0% | -67.1% | ||
| Q4 24 | 110.3% | -3.8% | ||
| Q3 24 | 35.5% | -30.9% | ||
| Q2 24 | 6.8% | -13.9% |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 0.2% | ||
| Q3 25 | 2.3% | 0.3% | ||
| Q2 25 | 1.2% | 0.6% | ||
| Q1 25 | 0.8% | 0.9% | ||
| Q4 24 | 28.1% | 0.4% | ||
| Q3 24 | 8.1% | 0.3% | ||
| Q2 24 | 5.6% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 5.38× | — | ||
| Q3 25 | 6.88× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 7.60× | — | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
